- Home
- STGW vs ELVN Comparison
STGW vs ELVN Comparison
Compare STGW & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- ELVN
- Stock Information
- Founded
- STGW 1980
- ELVN 2016
- Country
- STGW United States
- ELVN United States
- Employees
- STGW N/A
- ELVN N/A
- Industry
- STGW
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- STGW
- ELVN Health Care
- Exchange
- STGW Nasdaq
- ELVN Nasdaq
- Market Cap
- STGW 1.2B
- ELVN 1.2B
- IPO Year
- STGW N/A
- ELVN 2020
- Fundamental
- Price
- STGW $4.65
- ELVN $22.63
- Analyst Decision
- STGW Strong Buy
- ELVN Strong Buy
- Analyst Count
- STGW 4
- ELVN 5
- Target Price
- STGW $9.13
- ELVN $41.20
- AVG Volume (30 Days)
- STGW 1.4M
- ELVN 721.5K
- Earning Date
- STGW 07-31-2025
- ELVN 08-12-2025
- Dividend Yield
- STGW N/A
- ELVN N/A
- EPS Growth
- STGW N/A
- ELVN N/A
- EPS
- STGW N/A
- ELVN N/A
- Revenue
- STGW $2,822,897,000.00
- ELVN N/A
- Revenue This Year
- STGW $4.88
- ELVN N/A
- Revenue Next Year
- STGW $11.07
- ELVN N/A
- P/E Ratio
- STGW N/A
- ELVN N/A
- Revenue Growth
- STGW 9.64
- ELVN N/A
- 52 Week Low
- STGW $4.03
- ELVN $13.30
- 52 Week High
- STGW $8.18
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- STGW 51.53
- ELVN 60.45
- Support Level
- STGW $4.48
- ELVN $19.38
- Resistance Level
- STGW $4.67
- ELVN $21.34
- Average True Range (ATR)
- STGW 0.16
- ELVN 1.27
- MACD
- STGW 0.05
- ELVN 0.11
- Stochastic Oscillator
- STGW 82.56
- ELVN 88.47
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.